Business
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference\n\n\n\n\n\nAmarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference\nPR Newswire\nSAN FRANCISCO, January 11, 2016\n\n\n\nSAN FRANCISCO, January 11, 2016 /PRNewswire/ --\n\nAmarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan diseases, today announced that President & CEO Gerald E. Commissiong will be presenting at 2pm PT at the First Annual SeeThruEquity Microcap Healthcare Investor Conference, held at 2pm PT January 11, 2016 at the Fairmont Hotel in San Francisco.\n\nThe Company will be providing an update on progress in regards to its upcoming Phase 2 clinical study of Engineered Skin Substitute (ESS) for the treatment of severe burns in collaboration with the US Army.\n\nAbout Amarantus BioScience Holdings, Inc. \n\nAmarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of Neurology, Regenerative Medicine and Orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS), an autologous full thickness skin replacement product in development for the treatment of adult severe burns, currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas.  ESS has achieved Orphan Drug Designation (ODD) in the area of severe burns, and is seeking ODD status for additional serious dermatologic indications. AMBS also has development rights to eltoprazine, a small molecule currently in clinical development for Parkinson's disease levodopa-induced dyskinesia, an orphan disorder, with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP) and retinal artery occlusion (RAO). AMBS also owns the technology platform th...